REGENXBIO Reports Third Quarter 2022 Financial Results and R

Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products...

Related Keywords

United States , Cyprus , American , Dana Cormack , Chris Brinzey , Ultragenyx Pharmaceutical Inc , Technology Platform , Technology Platform Licensees , American Academy Of Ophthalmology , Rocket Pharmaceuticals Inc , Nasdaq , Technology Licensee Program , Development Expenses , Exchange Commission , Corporate Communications , Securities Exchange , Manufacturing Innovation Center , Long Term Follow Up , Chief Executive Officer , Biologics License Application , American Academy , Duchenne Muscular Dystrophy , Mucopolysaccharidosis Type , Hunter Syndrome , Innovation Center , Licensee Program Highlights , Rocket Pharmaceuticals , Ultragenyx Pharmaceutical , Ornithine Transcarbamylase , Administrative Expenses , Platform Licensees , Securities Act , Securities Exchange Act , Financial Condition , Tax Benefit , Regenxbio Inc ,